TUKYSA is indicated in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. This indication is approved under accelerated approval based on tumor response rate and …

Monitor ALT, AST, and bilirubin before starting treatment, every 3 weeks during treatment, and as clinically indicated. Additional dosing and administration information 1. For patients with severe hepatic impairment (Child-Pugh C), the recommended starting dose …

TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Diarrhea. TUKYSA can cause severe diarrhea including dehydration, hypotension, acute kidney injury, and death 2; Median time to onset (any grade) was 12 days 2; Median time to resolution was 8 days 2; Median duration of antidiarrheal use was 3 days for each 21-day repeating regimen 1; Diarrhea led to TUKYSA dose reductions in 6% of patients and TUKYSA discontinuation in …

Learn about access and patient support programs for TUKSYA® (tucatinib) tablets for RAS WT HER2+ mCRC. Read full Indication and Important Safety Information.